Status:
UNKNOWN
Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis
Lead Sponsor:
University of Athens
Conditions:
Rheumatoid Arthritis
Inflammation
Eligibility:
All Genders
18-80 years
Brief Summary
Recent studies show beneficial effect of the inhibition of interleukin-6 (IL-6) activity on vascular and left ventricular (LV) function. The purpose of this study is to investigate whether anakinra, a...
Detailed Description
The inflammatory processes observed in patients with rheumatoid arthritis (RA) are strongly linked to enhanced interleukin-6 (IL-6) activity. Increased IL-6 activity causes myocardial cell damage and ...
Eligibility Criteria
Inclusion
- Patients with rheumatoid arthritis who had an inadequate response to disease modifying antirheumatic drugs (DMARDs) and corticosteroids and were going to initiate treatment with interleukin-6 inhibitor.
Exclusion
- Familiar hyperlipidemia
- Diabetes mellitus
- Chronic obstructive pulmonary disease or asthma
- Moderate or severe valvular heart disease
- Primary cardiomyopathies
- Malignant tumors
Key Trial Info
Start Date :
October 27 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03288584
Start Date
October 27 2017
End Date
December 31 2020
Last Update
April 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Attikon Hospital
Athens, Haidari, Greece, 12462